Coccidioidomycosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Aditya Ganti (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Coccidioidomycosis}} | {{Coccidioidomycosis}} | ||
{{CMG}}:{{AE}}{{ADG}} | |||
==Overview== | |||
Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective. | |||
==References== | ==References== | ||
Revision as of 18:33, 29 March 2017
Coccidioidomycosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Coccidioidomycosis cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Coccidioidomycosis cost-effectiveness of therapy |
Coccidioidomycosis cost-effectiveness of therapy in the news |
Risk calculators and risk factors for Coccidioidomycosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective.